A proliferation-inducing ligand (APRIL) from the tumor necrosis factor (TNF) superfamily co-stimulates B-cell activation. When overexpressed in mice, APRIL induces B-cell neoplasia. 1 The promoting activity of APRIL for B-cell derived tumors has been recently reported in vitro for human Hodgkin's lymphoma (HL) cell lines. 2 In this work, we sought to ascertain whether APRIL plays a role in the in situ development of HL with a particular emphasis on the pathway(s) involved.
We first confirmed the report from Chiu et al. 2 that soluble oligomerized APRIL, ACRP30-APRIL A88 , 3 provides a survival signal to the HL cell lines L428, L591 and KMH2 when placed under serum starvation. Molecularly, HL cell lines bound soluble APRIL (Figure 1a ). APRIL binding to HL cell lines was inhibited in part by heparin, a soluble heparan sulfate proteoglycan (HSPG) characterized as a APRIL-binding partner. 4 ,5 APRIL binding was also observed, although to a reduced level, with another soluble form of APRIL, APRIL H98 , lacking the membrane proximal domain interacting with HSPG. Hence, the transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and/or the B-cell maturation antigen (BCMA) were also involved in APRIL binding in addition to HSPG. An anti-syndecan-1 and an anti-BCMA stained specifically the surface of the L428 HL cell line (Figure 1b) . The L591 and KMH2 HL cell lines were also stained with the anti-BCMA but not with the anti-syndecan-1 (data not shown). As binding of APRIL A88 on L591 and KMH2 was also inhibited by heparin (data not shown), this indicates that another proteoglycan proteic core carrying heparan sulfate side chains served as APRIL-binding partner at the surface of L591 and KMH2. In contrast to BCMA, the second APRIL receptor belonging to the TNF receptor (TNF-R) superfamily, TACI was not detected at the surface of the HL cell line. Absence of staining was observed with seven different anti-TACI monoclonal antibodies, all validated for flow cytometry on the IM9 B-cell line. BAFF-R, another member of the TNF-R family that may also bind to APRIL in some circumstances, 6 was also not expressed on the HL cell lines. Absence of TACI expression was confirmed by sensitive (40 cycles) reverse transcription-PCR (RT-PCR) analysis in L428 and KMH2, whereas L591 produced a detectable band for TACI mRNA (data not shown). The discrepancy between mRNA and surface protein expression for TACI in L591 warrants Letters to the Editor resolving this issue. In contrast to its receptors, endogenous APRIL protein expression was not detected in the HL cell lines with the Stalk-1 antibody 3 ( Figure 1c ), a result that was confirmed at the level of mRNA expression with sensitive RT-PCR (data not shown). Taken together, this in vitro analysis indicates that HL cell lines express HSPG as binding partner, and BCMA as signaling receptor for APRIL, explaining their responsiveness to exogenous APRIL.
As APRIL expression was not detected in HL cell lines, contrasting with the report from Chiu et al.,
2 the cellular source of APRIL expression was studied in situ in HL lesions by immunohistochemistry using a pair of APRIL-specific antibodies. Aprily-2 detects the C-terminal TNF-homology domain that is secreted upon furin cleavage, and Stalk-1 detects a membrane-proximal part of the APRIL extracellular domain remaining associated with producer cells. Immunohistochemical staining with Stalk-1 and Aprily-2 allows in situ dissection of APRIL-producing cells and secreted APRIL, respectively. 3 Immunostaining of a tumor tissue micro-array allowed us to analyze 285 cHL cases including nodular sclerosis (n ¼ 170), mixed cellularity (n ¼ 89), lymphocyte-rich (n ¼ 7), lymphocytedepleted (n ¼ 6) and unclassified nodular lymphocyte predominant (n ¼ 13) cases. Significant APRIL staining ('APRIL high') was observed in 64% (182/285) of the cases, and the remaining HL cases showed only focal or absent staining ('APRIL low') ( Table 1 ). There was no significant association of high level of APRIL expression with cHL subtypes constituting the TMA In situ APRIL expression was analyzed with Stalk-1 and Aprily-2 antibodies. Ranking of APRIL expression was carried out as previously described. In situ APRIL expression in cHL. Hodgkin tumor lesions were stained with Aprily-2 (2 mg/ml) and Stalk-1 (5 mg/ml) antibodies followed by biotinylated goat anti-rabbit or anti-mouse serum (Jackson, Immunoresearch, West Grove, PA, USA), StreptABCcomplex/HRP (Dako, Glostrup, Denmark) and 3-amino-9-ethylcarbazole substrate (Sigma). Letters to the Editor analyzed here. Indeed, nodular sclerosis and mixed cellularity cases presented a similar proportion of APRIL high lesions. Figure 2a shows a representative cHL case expressing high level of APRIL with a strong Aprily-2 staining, associated with abundant cells stained with Stalk-1 in the lesion (upper panel). A representative case with a lesion devoid of APRIL staining, both for Aprily-2 and Stalk-1, is also shown (lower panel). Morphologically characteristic HRS cells (arrows in Figure 2) were not stained by Stalk-1, but some of the Aprily-2 signals appeared to be associated to HRS cells. High-power microscopy confirmed that secreted APRIL accumulated onto cells with a morphology characteristic of HRS cells (Figure 2b) . To identify the nature of APRIL-producing cells, we performed two-color immunofluorescence stainings. Stalk-1-stained cells were positive for elastase, a protease that is specifically expressed in neutrophils (Figure 3a) . The neutrophil identity was further confirmed by a staining for CD15 and absence of eosinophilic or basophilic granulocytes, as assessed by eosin and IgE staining respectively (data not shown). In a minor fraction of cases, some elastase-negative cells were stained with Stalk-1, usually with a less intense staining (data not shown). These Stalk1-positive cells were histiocytes expressing the L1 protein as previously reported. 3 The TNF-R CD30 constitutes a marker for HRS cells in cHL lesions. CD30-positive HRS cells did not stain for Stalk-1, formally demonstrating that tumor cells did not produce APRIL in HL lesions (Figure 3b ). We reported in Figure 1 that HL cell lines express BCMA and HSPG, as APRIL receptor at their surface. Detection of endogenous BCMA is not possible to date in paraffin-embedded human tissues due to lack of reactive antibodies. For HSPG, the L428 cell line established from an HL patient expressed syndecan-1. In the cohort used here, syndecan-1 expression was confirmed in situ. Notably, staining for secreted APRIL colocalized with some of the syndecan-1 staining in these lesions (Figure 3c ). This indicates a tight interaction of secreted APRIL with HSPG in situ. Together, our findings indicate that APRIL expression was upregulated in a significant fraction of cHL disease lesions. The major source of APRIL production is not the HRS cell but rather infiltrating neutrophils. In the lesions, APRIL secreted by neutrophils concentrated onto or close to tumor cells, bound to HSPG.
Tumor promotion by host inflammatory reactions is an emerging concept. 7 In HL, it is widely accepted that the development of HRS tumor cells is tightly dependent on their interactions with host cells. 8 Neutrophils infiltrating HL lesions and secreting APRIL constitute one such interaction that benefits tumor development. The tumor-promoting activity of APRIL highlighted here in situ is unlikely to modulate the primary treatment efficacy of HL. Indeed, failure of initial treatment has become a too rare event 8 compared to the number of patients harboring APRIL upregulation. Hence, despite its tumorpromoting activity, APRIL may not constitute an attractive target for the primary treatment of HL. Whether APRIL plays a more relevant role in refractory or relapsed HL cases, which still constitute a clinical burden, 8 needs to be further evaluated. Children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of 21q have been identified previously as a new cytogenetic subgroup 1,2 with a frequency of 1.5% in a large series of patients. 3 The amplification is most often detected as multiple copies of RUNX1 (AML1) signals, which are seen as clusters during interphase fluorescence in situ hybridization (FISH) analysis using ETV6/RUNX1 probes. The common region of amplification (CRA) spanning 6.5-6.6 Mb was recently reported using high-resolution array-CGH of chromosome 21 and the whole genome changes were characterized using BAC array-CGH with a resolution of 1 Mb. 4 We have used a tiling resolution 33 K BAC array and interphase FISH to investigate seven children with ALL with intrachromosomal amplification of 21q to characterize in detail the amplified region, as well as any additional genomic imbalances. We have also tested a possible mechanism by which this amplification could occur (see Materials and methods section in Supplementary Information).
Seven children with ALL, treated at Karolinska University Hospital 1997-2006, were diagnosed with amplification of 21q by FISH and included in the study. The project was approved by the Research Ethics Committee at Karolinska Institutet. The patients shared the characteristic features reported for other ALL patients with 21q amplification, as older age of onset (7-15 years old) and low white blood cell count at diagnosis (Supplementary Table 1 ). Patients with 21q amplification are currently treated as high risk in at least one protocol (UKALL 2003), but not in others, for example the ongoing Nordic protocol NOPHO ALL-2000. A recently published report assessing the relationship between intrachromosomal amplification of 21q and event-free survival in 28 ALL patients established clear evidence for adverse prognosis in the specific group of patients with a 5-year event-free survival of 29% when the patients were treated according to the UK MRC ALL97 protocol. 5 In the present study, patient no. 1 was treated as standard risk (SR), patient no. 2 as high risk (HR) owing to bulky lymphomatous organ involvement at diagnosis, and the remaining patients were stratified into the intermediate-risk (IR) group according to the NOPHO ALL-92 and NOPHO ALL-2000 protocols. In spite of a median observation time of 58 months (range, 15-119 months), only one of the IR patients has relapsed. This emphasizes the need to gather knowledge about this group of patients to provide an accurate risk assessment at diagnosis.
Genetic analyses including karyotyping by G-banding, SKY and interphase FISH for BCR/ABL, ETV6/RUNX1, PBX1/TCF3 and MLL rearrangements, as well as 9p21 deletion were performed as part of the routine investigation. Only two patients had abnormalities detected by G-banding (nos. 3 and 5). Amplification of 21q was suspected by interphase FISH analysis on diagnostic bone marrow smears using the ETV6/RUNX1 probe. The number of gene copies varied between 4 and 15 in different samples and between 3-4 and 12-15 in different cells from the same patient. The results of array-CGH are shown in Table 1 . Overall, we performed array-CGH on nine samples: seven diagnostic and two relapse samples (from case no. 3). In case no. 1, no unbalanced changes were detected on
